Clario's New AI-Powered ECG Quality Score Tool Enhances Cardiac Safety Assessments

Ellen Street, Executive Vice President, Cardiac Safety at Clario, expressed the company's enthusiasm, stating, "Clario's ECG Quality Score tool embodies our unwavering commitment to advancing trials and technologies through the use of AI/ML. We aim to provide sponsors with better insights into cardiac safety earlier in the drug development process and equip them with the tools needed to make informed decisions and collect higher quality data." Ellen Street, Executive Vice President, Cardiac...

Ellen Street, Executive Vice President, Cardiac Safety at Clario, expressed the company's enthusiasm, stating, "Clario's ECG Quality Score tool embodies our unwavering commitment to advancing trials and technologies through the use of AI/ML. We aim to provide sponsors with better insights into cardiac safety earlier in the drug development process and equip them with the tools needed to make informed decisions and collect higher quality data."

The ECG Quality Score tool includes two detailed reports – the Early Precision QT^® Quality Summary Report and the Early Precision QT^® Quality Detailed Report – which together provide granular information about the quality of ECG data collected. It offers valuable insights and reassurance to sponsors by enhancing data quality assurance, reducing risks, and ultimately improving the likelihood of a definitive trial outcome, making it a valuable addition to Clario's cardiac safety services. Initially, it will be rolled out to Clario Certified Sites as part of our focus on bringing new technology to our closest partners first.

For more information on Quality Score or on becoming a Certified Site, please visit Clario.com.

Contact Information
Duncan Cantor
Sr. Director, Corporate Communications
media@clario.com

About Clario

Clario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized, hybrid and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. With 11 facilities in six countries, Clario's global team of science, technology and operational experts has helped deliver over 27,000 trials and more than 500 regulatory approvals since 2012 for over five million patients in 120 countries. Our innovation has been transforming clinical trials for 50 years.

For more information, go to Clario.com or follow us on LinkedIn and Twitter

Logo - https://mma.prnewswire.com/media/1677749/Clario_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/clarios-new-ai-powered-ecg-quality-score-tool-enhances-cardiac-safety-assessments-301998213.html